Molecular Targeting of VEGF with a Suramin Fragment–DOCA Conjugate by Mimicking the Action of Low Molecular Weight Heparins
Open Access
- 31 December 2020
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (1) , 46
Abstract
Molecular targeting of growth factors has shown great therapeutic potential in pharmaceutical research due to their roles in pathological conditions. In the present study, we developed a novel suramin fragment and deoxycholic acid conjugate (SFD) that exhibited the potential to bind to the heparin-binding site (HBD) of vascular endothelial growth factor (VEGF) and to inhibit its pathogenic action for the first time. Notably, SFD was optimally designed for binding to the HBD of VEGF using the naphthalenetrisulfonate group, allowing to observe its excellent binding efficacy in a surface plasmon resonance (SPR) study, showing remarkable binding affinity (KD = 3.8 nM) as a small molecule inhibitor. In the tubular formation assay, it was observed that SFD could bind to HBD and exhibit antiangiogenic efficacy by inhibiting VEGF, such as heparins. The cellular treatment of SFD resulted in VEGF-inhibitory effects in human umbilical vein endothelial cells (HUVECs). Therefore, we propose that SFD can be employed as a novel drug candidate to inhibit the pathophysiological action of VEGF in diseases. Consequently, SFD, which has a molecular structure optimized for binding to HBD, is put forward as a new chemical VEGF inhibitor.Keywords
This publication has 44 references indexed in Scilit:
- The p53 family and VEGF regulation: “It’s complicated”Cell Cycle, 2013
- Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharidesBioscience Reports, 2011
- High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivativesJournal of Controlled Release, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Understanding the Mechanism of the Antimitogenic Activity of SuraminBiochemistry, 2005
- Structural Basis for Antagonism by Suramin of Heparin Binding to Vaccinia Complement Protein,Biochemistry, 2005
- Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic ActionJournal of Molecular and Cellular Cardiology, 1996
- Therapeutic uses of heparin beyond its traditional role as an anticoagulantTrends in Pharmacological Sciences, 1995
- Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of CortisoneScience, 1983
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971